Bariatric Surgery for Obesity at Age 65 and Beyond: A Cardiovascular Win
A large Medicare database analysis provides some of the best evidence to date that bariatric surgery’s cardiovascular benefits extend even to patients aged 65 or older.
Bariatric surgery is associated with a significantly reduced risk of mortality and adverse cardiovascular events in patients with obesity, including those 65 to 75 years old, a population often deemed inappropriate for this important weight reduction strategy. So found a Cleveland Clinic-led observational study of nearly 190,000 Medicare beneficiaries with obesity followed for a median of four years. The study was published in the Journal of the American College of Cardiology.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
“Our findings of cardiovascular benefits of bariatric surgery in older patients with obesity were significant, including more than halving the risk of new-onset heart failure,” says the study’s corresponding author, Amgad Mentias, MD, a Cleveland Clinic cardiologist. “Benefits were apparent in both men and women, across all ages within our cohort, and whether or not patients had diabetes.”
Despite considerable evidence that bariatric surgery is the most effective treatment available for severe obesity, its role in long-term cardiovascular risk reduction has not been well studied in a nationwide real-world cohort in the United States, especially among patients older than 65 years and those without diabetes.
This large study, using a Medicare database and advanced statistical methods, was designed to address these gaps.
The Medicare Provider Analysis and Review (MedPAR) database, which contains records for all Medicare beneficiaries who use hospital inpatient services, was examined for patients diagnosed with obesity from 2013 through 2019. Those with an urgent admission or discharged to any destination other than home were excluded, as were patients older than 75 years or who had established heart failure.
The resulting study cohort consisted of 94,885 Medicare beneficiaries who underwent bariatric surgery during that period. Nearly two-thirds had sleeve gastrectomy, one-third had gastric bypass and 1.3% had gastric banding. The control group consisted of the same number of patients with obesity who did not undergo bariatric surgery, matched 1:1 to the bariatric surgery group by exact age, sex, race, body mass index and propensity score matching using 87 other clinical variables.
Both groups were 70% female and had similar mean age (62.3 ± 10.6 years) and body mass index (44.7 kg/m2 ± 7.3; range, 30-70 kg/m2).
After median follow-up of 4.0 years (interquartile range, 2.4-5.7), the bariatric surgery group was found to have reduced risk of the following adverse outcomes relative to controls:
These factors did not differ significantly in men versus women or according to the presence or absence of diabetes at baseline.
Instrumental variable analysis — a statistical method that mimics randomized clinical trials — was subsequently used to adjust for potential confounders. With this technique, risk reductions in the bariatric surgery group were 60% for all-cause mortality, 79% for new-onset heart failure and 80% for myocardial infarction compared with the control group. No significant difference was found for stroke incidence.
The combined incidence of in-hospital and 30-day mortality was less than 0.3% in patients who underwent bariatric surgery.
The results of this study are consistent with those of smaller studies showing cardiovascular benefit from bariatric surgery. The authors note the following key findings this study adds to the evidence base:
“Despite the substantial benefits of bariatric surgery, it is used in fewer than 1% of patients who are potential candidates,” observes the study’s senior author, Milind Desai, MD, MBA, Director of Clinical Operations in Cleveland Clinic’s Heart, Vascular & Thoracic Institute. “Clinicians should be discussing this option when appropriate, even with their older patients.”
“With the availability of new medications for weight loss, such as glucagon like peptide-1 analogues, their effectiveness and cardiovascular benefits should be compared with bariatric surgery in future studies,” adds Dr. Mentias.